Compare Cincinnati Financial Corporation (CINF) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Incyte Corporation — how do they compare? Cincinnati Financial Corporation trades at $172.59 (market cap $26.58B), while Incyte Corporation trades at $120.85 (market cap $24.54B). The key difference: Cincinnati Financial Corporation and Incyte Corporation are close in size by market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CINF | INCY | |
|---|---|---|
Market Cap | $26.58B | $24.54B |
Sector | Financials | Health |
52-Week High | $192.03 | $129.93 |
52-Week Low | $149.79 | $81.61 |
Enterprise Value | $25.71B | $20.04B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $173.86, down 1.7% on the day, with a bearish technical signal and key support at $172. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and a consistent dividend history, with a recent H1-26 dividend of $0.94 declared.
The outlook is cautiously optimistic, supported by a consensus price target of $195 and a 'Moderate Buy' analyst rating. Risks include catastrophe losses impacting underwriting and competitive pressures in commercial lines. Positive cash flow trends and rising investment income provide a solid foundation for long-term growth.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
